Replimune Group Inc (REPL)
10.80
-0.60
(-5.26%)
USD |
NASDAQ |
Nov 15, 16:00
10.80
0.00 (0.00%)
After-Hours: 20:00
Replimune Group Cash from Investing (Quarterly): 0.458M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 0.458M |
June 30, 2024 | 29.77M |
March 31, 2024 | 23.20M |
December 31, 2023 | 53.96M |
September 30, 2023 | 12.68M |
June 30, 2023 | 7.361M |
March 31, 2023 | -22.75M |
December 31, 2022 | -125.10M |
September 30, 2022 | 0.036M |
June 30, 2022 | 5.315M |
March 31, 2022 | -4.326M |
December 31, 2021 | -13.42M |
September 30, 2021 | -11.05M |
June 30, 2021 | 26.99M |
March 31, 2021 | -126.27M |
Date | Value |
---|---|
December 31, 2020 | 31.42M |
September 30, 2020 | -44.80M |
June 30, 2020 | -49.13M |
March 31, 2020 | 7.841M |
December 31, 2019 | -65.21M |
September 30, 2019 | 25.32M |
June 30, 2019 | 26.81M |
March 31, 2019 | 10.47M |
December 31, 2018 | 3.801M |
September 30, 2018 | -85.11M |
June 30, 2018 | 4.89M |
March 31, 2018 | -18.08M |
December 31, 2017 | -25.84M |
September 30, 2017 | -0.101M |
June 30, 2017 | -0.033M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-126.27M
Minimum
Mar 2021
53.96M
Maximum
Dec 2023
-13.15M
Average
0.247M
Median
Cash from Investing (Quarterly) Benchmarks
Bristol-Myers Squibb Co | -219.00M |
Nuvalent Inc | -212.91M |
NovaBay Pharmaceuticals Inc | -0.002M |
Palatin Technologies Inc | -0.0049M |
iBio Inc | -0.144M |
Cash from Investing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -38.64M |
Cash from Financing (Quarterly) | -0.039M |
Free Cash Flow | -188.31M |
Free Cash Flow Per Share (Quarterly) | -0.5183 |
Free Cash Flow Yield | -24.81% |